ERBB2 and cancer: The HER2-enriched breast cancer is typically associated with ILC, and it is responsible for 10–15% of all breast cancers, presenting a high expression of Ki-67 (>20%), which makes this cancer the one with worse prognosis and with the fastest pace of growth in comparison to luminal breast cancer [79,80,81].